补体抑制剂临床使用中感染预防的实践考量
补体系统过度激活参与IgA肾病、C3肾小球病、非典型溶血性尿毒症综合征和ANCA相关性血管炎等严重肾脏病的病理生理过程。美国FDA已批准五种补体抑制剂(eculizumab、ravulizumab、avacopan、iptacopan和pegcetacoplan)用于治疗肾脏病,但部分药物可能增加严重甚至危及生命的感染风险,尤其是荚膜菌感染。本综述总结了补体抑制剂的感染风险,并强调安全有效使用这些药物的关键临床考量,旨在为临床医生提供实用资源。
要点
- 五种补体抑制剂已获FDA批准用于肾脏病治疗,但部分药物增加荚膜菌感染风险。
- 医护人员处方补体抑制剂时须识别感染风险并采取预防措施。
- 本综述为临床使用补体抑制剂的医生提供感染预防的实用参考。
核心结论
- 补体抑制剂治疗肾脏病时可能增加严重感染风险,医护人员应识别风险并实施预防措施以确保安全有效使用。
研究设计与样本
- 综述,总结补体抑制剂的感染风险及临床使用中的关键考量。
主要发现
- 补体系统过度激活参与IgA肾病、C3肾小球病、非典型溶血性尿毒症综合征和ANCA相关性血管炎的病理生理。
- 美国FDA已批准eculizumab、ravulizumab、avacopan、iptacopan和pegcetacoplan五种补体抑制剂用于治疗肾脏病。
- 部分补体抑制剂可能增加严重、潜在危及生命的感染风险,尤其是荚膜菌如脑膜炎奈瑟菌、肺炎链球菌和b型流感嗜血杆菌。
临床怎么用
- 处方补体抑制剂时应识别感染风险并实施预防措施。
- 本综述可作为临床医生使用补体抑制剂治疗肾脏病的实用资源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Overactivation of the complement system plays a role in the pathophysiology of several serious kidney diseases, such as IgA nephropathy, complement 3 glomerulopathy, atypical hemolytic uremic syndrome, and ANCA-associated vasculitis. A key focus of recent research has been developing complement inhibitors to target the underlying disease mechanisms of these diseases and thereby improve patient outcomes. Currently, five complement inhibitors are approved by the US Food and Drug Administration as effective for the treatment of kidney diseases: eculizumab, ravulizumab, avacopan, iptacopan, and pegcetacoplan. However, some of these therapies may increase the risk of serious, potentially life-threatening infections, particularly from encapsulated organisms including Neisseria meningitidis , Streptococcus pneumoniae , and Haemophilus influenzae type b. Health care providers must recognize this risk and implement preventive measures when prescribing complement inhibitors. This review summarizes the infectious risks associated with complement inhibitors and highlights key clinical considerations for their safe and effective use in the treatment of kidney diseases. It is intended to serve as an accessible resource for providers using these agents in clinical practice.
引用
- Java A, Subramanian A, Nester C, et al. Practical Considerations for Infection Prevention with the Clinical Use of Complement Inhibitors. Clin J Am Soc Nephrol. 2026. PMID: 41649885. doi:10.2215/CJN.0000001020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。